Kiniksa inks li­cens­ing deal to take a Re­gen­eron castoff in­to Asian mar­kets

Af­ter dig­ging through Re­gen­eron’s trash bin, Kiniksa has man­aged to put to­geth­er a tiny run with the ag­ing drug Ar­c­a­lyst in re­cent years. Now, the com­pa­ny will look to break through in Asian mar­kets.

Huadong Med­i­cine will pay $22 mil­lion up­front and a po­ten­tial $640 mil­lion in down­stream mile­stones to ex­clu­sive­ly li­cense Kiniksa’s Ar­c­a­lyst, an IL-1α and IL-1β block­er, and Covid-19 an­ti­body can­di­date mavril­i­mum­ab in Asian mar­kets not in­clud­ing Japan, the part­ners said Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER